1098 related articles for article (PubMed ID: 28583305)
1. Immunogenicity and safety of a new hexavalent vaccine (DTaP5-IPV-HB-Hib) administered in a mixed primary series schedule with a pentavalent vaccine (DTaP5-IPV-Hib).
Martinón-Torres F; Boisnard F; Thomas S; Sadorge C; Borrow R;
Vaccine; 2017 Jun; 35(30):3764-3772. PubMed ID: 28583305
[TBL] [Abstract][Full Text] [Related]
2. Safety and immunogenicity of a toddler dose following an infant series of a hexavalent diphtheria, tetanus, acellular pertussis, inactivated poliovirus, Haemophilus influenzae type b, hepatitis B vaccine administered concurrently or at separate visits with a heptavalent pneumococcal conjugate vaccine.
Halperin SA; Tapiéro B; Dionne M; Meekison W; Diaz-Mitoma F; Zickler P; Rubin E; Embree J; Bhuyan P; Lee A; Li M; Tomovici A
Pediatr Infect Dis J; 2014 Jan; 33(1):73-80. PubMed ID: 24346596
[TBL] [Abstract][Full Text] [Related]
3. Concomitant administration of a fully liquid, ready-to-use DTaP-IPV-HB-PRP-T hexavalent vaccine with a meningococcal serogroup C conjugate vaccine in infants.
Vesikari T; Borrow R; Da Costa X; Richard P; Eymin C; Boisnard F; Lockhart S
Vaccine; 2017 Jan; 35(3):452-458. PubMed ID: 27939054
[TBL] [Abstract][Full Text] [Related]
4. Disparate kinetics in immune response of two different
Martinón-Torres F; Salamanca de la Cueva I; Horn M; Westerholt S; Bosis S; Meyer N; Cheuvart B; Virk N; Jakes RW; Duchenne M; Van den Steen P
Hum Vaccin Immunother; 2024 Dec; 20(1):2342630. PubMed ID: 38687024
[TBL] [Abstract][Full Text] [Related]
5. Immunogenicity and safety following primary and booster vaccination with a hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus and Haemophilus influenzae type b vaccine: a randomized trial in the United States.
Klein NP; Abu-Elyazeed R; Cheuvart B; Janssens W; Mesaros N
Hum Vaccin Immunother; 2019; 15(4):809-821. PubMed ID: 30444673
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the reactogenicity and immunogenicity of a combined diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated polio (DTPa-HBV-IPV) vaccine, mixed with the Haemophilus influenzae type b (Hib) conjugate vaccine and administered as a single injection, with the DTPa-IPV/Hib and hepatitis B vaccines administered in two simultaneous injections to infants at 2, 4 and 6 months of age.
Arístegui J; Dal-Ré R; Díez-Delgado J; Marés J; Casanovas JM; García-Corbeira P; De Frutos E; Van Esso D; Verdaguer J; De la Flor J; Moraga F; Boceta R; García-Martínez JA
Vaccine; 2003 Sep; 21(25-26):3593-600. PubMed ID: 12922087
[TBL] [Abstract][Full Text] [Related]
7. Immunization of preterm infants with GSK's hexavalent combined diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus-Haemophilus influenzae type b conjugate vaccine: A review of safety and immunogenicity.
Omeñaca F; Vázquez L; Garcia-Corbeira P; Mesaros N; Hanssens L; Dolhain J; Gómez IP; Liese J; Knuf M
Vaccine; 2018 Feb; 36(7):986-996. PubMed ID: 29336924
[TBL] [Abstract][Full Text] [Related]
8. A Phase III Randomized, Double-blind, Clinical Trial of an Investigational Hexavalent Vaccine Given at Two, Three, Four and Twelve Months.
Vesikari T; Becker T; Vertruyen AF; Poschet K; Flores SA; Pagnoni MF; Xu J; Liu GF; Stek JE; Boisnard F; Thomas S; Ziani E; Lee AW
Pediatr Infect Dis J; 2017 Feb; 36(2):209-215. PubMed ID: 27846055
[TBL] [Abstract][Full Text] [Related]
9. A Phase III randomized, double-blind, clinical trial of an investigational hexavalent vaccine given at 2, 4, and 11-12 months.
Silfverdal SA; Icardi G; Vesikari T; Flores SA; Pagnoni MF; Xu J; Liu GF; Stek JE; Boisnard F; Thomas S; Ziani E; Lee AW
Vaccine; 2016 Jul; 34(33):3810-6. PubMed ID: 27288217
[TBL] [Abstract][Full Text] [Related]
10. Immunogenicity and reactogenicity of primary immunization with a hexavalent diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio-Haemophilus influenzae type B vaccine coadministered with two doses of a meningococcal C-tetanus toxoid conjugate vaccine.
Tejedor JC; Moro M; Ruiz-Contreras J; Castro J; Gómez-Campderá JA; Navarro ML; Merino JM; Martín-Ancel A; Roca J; García-del-Río M; Jurado A; Díez-Delgado FJ; Omeñaca F; García-Sicilia J; Boceta R; García-Corbeira P; Jacquet JM; Collard A; Schuerman L;
Pediatr Infect Dis J; 2006 Aug; 25(8):713-20. PubMed ID: 16874171
[TBL] [Abstract][Full Text] [Related]
11. Integrated Safety Profile of a New Approved, Fully Liquid DTaP5-HB-IPV-Hib Vaccine.
Xu J; Stek JE; Ziani E; Liu GF; Lee AW
Pediatr Infect Dis J; 2019 Apr; 38(4):439-443. PubMed ID: 30882742
[TBL] [Abstract][Full Text] [Related]
12. Immunogenicity and safety of primary and booster vaccination with 2 investigational formulations of diphtheria, tetanus and Haemophilus influenzae type b antigens in a hexavalent DTPa-HBV-IPV/Hib combination vaccine in comparison with the licensed Infanrix hexa.
Vesikari T; Rivera L; Korhonen T; Ahonen A; Cheuvart B; Hezareh M; Janssens W; Mesaros N
Hum Vaccin Immunother; 2017 Jul; 13(7):1505-1515. PubMed ID: 28340322
[TBL] [Abstract][Full Text] [Related]
13. DTaP5-IPV-Hib-HepB, a hexavalent vaccine for infants and toddlers.
Lee AW; Jordanov E; Boisnard F; Marshall GS
Expert Rev Vaccines; 2017 Feb; 16(2):85-92. PubMed ID: 27996332
[TBL] [Abstract][Full Text] [Related]
14. Concomitant administration of a fully liquid ready-to-use DTaP-IPV-HB-PRP-T hexavalent vaccine with a meningococcal ACWY conjugate vaccine in toddlers.
Vesikari T; Borrow R; Da Costa X; Thomas S; Eymin C; Boisnard F; Lockhart S
Vaccine; 2018 Dec; 36(52):8019-8027. PubMed ID: 30471953
[TBL] [Abstract][Full Text] [Related]
15. Immunogenicity and reactogenicity of two regimens of diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio and Haemophilus influenzae type b vaccines administered to infants primed at birth with hepatitis B vaccine.
Cheng HK; Rajadurai VS; Amin Z; Sriram B; Yee MF; Han HH; Bock HL; Safary A
Southeast Asian J Trop Med Public Health; 2004 Sep; 35(3):685-92. PubMed ID: 15689088
[TBL] [Abstract][Full Text] [Related]
16. Combined Haemophilus influenzae type b and Neisseria meningitidis serogroup C (HibMenC) or serogroup C and Y-tetanus toxoid conjugate (and HibMenCY) vaccines are well-tolerated and immunogenic when administered according to the 2,3,4 months schedule with a fourth dose at 12-18 months of age.
Habermehl P; Leroux-Roels G; Sänger R; Mächler G; Boutriau D
Hum Vaccin; 2010 Aug; 6(8):640-51. PubMed ID: 20697200
[TBL] [Abstract][Full Text] [Related]
17. A randomized, controlled trial to assess the immunogenicity and safety of a heptavalent diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, hib and meningococcal serogroup C combination vaccine administered at 2, 3, 4 and 12-18 months of age.
Szenborn L; Czajka H; Brzostek J; Konior R; Caubet M; Ulianov L; Leyssen M
Pediatr Infect Dis J; 2013 Jul; 32(7):777-85. PubMed ID: 23838777
[TBL] [Abstract][Full Text] [Related]
18. Safety and immunogenicity of a hexavalent diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine at 2, 3, 4, and 12-14 months of age.
Halperin SA; Tapiero B; Diaz-Mitoma F; Law BJ; Hoffenbach A; Zappacosta PS; Radley D; McCarson BJ; Martin JC; Brackett LE; Boslego JW; Hesley TM; Bhuyan PK; Silber JL
Vaccine; 2009 Apr; 27(19):2540-7. PubMed ID: 19124057
[TBL] [Abstract][Full Text] [Related]
19. A randomized study to evaluate the immunogenicity and safety of a heptavalent diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, haemophilus influenzae b, and meningococcal serogroup C combination vaccine administered to infants at 2, 4 and 12 months of age.
Thollot F; Scheifele D; Pankow-Culot H; Cheuvart B; Leyssen M; Ulianov L; Miller JM
Pediatr Infect Dis J; 2014 Dec; 33(12):1246-54. PubMed ID: 25037033
[TBL] [Abstract][Full Text] [Related]
20. Safety and immunogenicity of a hexavalent vaccine administered at 2, 4 and 6 months of age with or without a heptavalent pneumococcal conjugate vaccine: a randomized, open-label study.
Tapiéro B; Halperin SA; Dionne M; Meekison W; Diaz-Mitoma F; Zickler P; Rubin E; Embree J; Bhuyan P; Lee AW; Li M; Tomovici A
Pediatr Infect Dis J; 2013 Jan; 32(1):54-61. PubMed ID: 23241989
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
